Advertisement
Research ArticleDrug Discovery and Translational Medicine
Open Access

Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities

Marie-Laure Ozoux, Véronique Briand, Michel Pelat, Fabrice Barbe, Paul Schaeffer, Philippe Beauverger, Bruno Poirier, Jean-Michel Guillon, Frédéric Petit, Jean-Michel Altenburger, Jean-Pierre Bidouard and Philip Janiak
Journal of Pharmacology and Experimental Therapeutics July 2020, 374 (1) 24-37; DOI: https://doi.org/10.1124/jpet.120.265496

Abstract

Chronic kidney disease (CKD) remains a common disorder, leading to growing health and economic burden without curative treatment. In diabetic patients, CKD may result from a combination of metabolic and nonmetabolic-related factors, with mortality mainly driven by cardiovascular events. The marked overactivity of the urotensinergic system in diabetic patients implicates this vasoactive peptide as a possible contributor to the pathogenesis of renal as well as heart failure. Previous preclinical studies with urotensin II (UII) antagonists in chronic kidney disease were based on simple end points that did not reflect the complex etiology of the disease. Given this, our studies revisited the therapeutic value of UII antagonism in CKD and extensively characterized 1-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-(2-methylphenyl)pyridin-2-yl]carbonyl}amino) cyclohexanecarboxylic acid hydrochloride (SAR101099), a potent, selective, and orally long-acting UII receptor competitive antagonist, inhibiting not only UII but also urotensin-related peptide activities. SR101099 treatment more than halved proteinurea and albumin/creatinine ratio in spontaneously hypertensive stroke-prone (SHR-SP) rats fed with salt/fat diet and Dahl-salt–sensitive rats, respectively, and it halved albuminuria in streptozotocin-induced diabetes rats. Importantly, these effects were accompanied by a decrease in mortality of 50% in SHR-SP and of 35% in the Dahl salt-sensitive rats. SAR101099 was also active on CKD-related cardiovascular pathologies and partly preserved contractile reserve in models of heart failure induced by myocardial infarction or ischemia/reperfusion in rats and pigs, respectively. SAR101099 exhibited a good safety/tolerability profile at all tested doses in clinical phase-I studies. Together, these data suggest that CKD patient selection considering comorbidities together with new stratification modalities should unveil the urotensin antagonists’ therapeutic potential.

SIGNIFICANCE STATEMENT Chronic kidney disease (CKD) is a pathology with growing health and economic burden, without curative treatment. For years, the impact of urotensin II receptor (UT) antagonism to treat CKD may have been compromised by available tools or models to deeper characterize the urotensinergic system. New potent, selective, orally long-acting cross-species UT antagonist such as SAR101099 exerting reno- and cardioprotective effects could offer novel therapeutic opportunities. Its preclinical and clinical results suggest that UT antagonism remains an attractive target in CKD on top of current standard of care.

Introduction

Chronic kidney disease (CKD) is a common pathology affecting around 10% of the total population (Lees et al., 2019). It has an indirect impact on global morbidity and mortality by increasing the risks associated with cardiovascular diseases (CVD), diabetes, hypertension, and infection with human immunodeficiency virus or malaria (Anavekar et al., 2004; Luyckx et al., 2018). However, there is no curative treatment of CKD. The current therapeutic strategy is based on risk factor management, but this is insufficient to curb the growing health and economic burden.

Cellular and molecular drivers of CKD pathogenesis remain unclear. Key features among others include focal segmental glomerulosclerosis with mesangial expansion and podocyte function impairment, tubulointerstitial inflammation, renal arteriolar lesions, or necrosis. Beyond the standard of care limited to angiotensin-converting enzyme (ACE) inhibitors or angiotensin AT1 receptor blockers, identification of new targets for CKD together with improved patient stratification is becoming critical for the development of transformative treatments. In this respect, the urotensinergic system might be reconsidered for targeted therapy in some CKD subgroups. The kidney is the major source of urotensin II (UII) in humans and animal species, and the urotensin II receptor (UT, G-Protein-coupled Receptor14) is expressed in renal tubules. Elevation in UII endogenous tone has also been recently demonstrated to contribute to the deterioration of renal function in rats (Eyre et al., 2019). UII is an 11-amino acid vasoactive peptide that possesses a highly conserved cyclic hexapeptide region from fish to mammals (Conlon et al., 1996; Coulouarn et al., 1999). It is known as one of the most potent vasoconstrictors identified so far (Ames et al., 1999; Douglas et al., 2000), but its effect is dependent on species and vascular beds (Gardiner et al., 2001; Behm et al., 2004; Tsoukas et al., 2011). UII and urotensin-related peptide (URP), which share the same cyclic hexapeptide region, are the endogenous selective ligands of UT. Components of urotensinergic system, including UII, URP, and UT, are widely expressed in the cardiovascular, renal, and endocrine systems (Castel et al., 2017).

The role of the UII system in human (patho)physiology is not yet fully understood. In humans, increased plasma UII concentrations have been associated with diabetes, chronic heart failure, or renal failure (Douglas et al., 2002; Richards et al., 2002; Totsune et al., 2003; Langham et al., 2004; Bousette and Giaid, 2006; Gruson et al., 2010). In human diabetic nephropathy, gene expression of UII and UT was markedly increased in comparison with controls, particularly in tubular epithelial cells (Langham et al., 2004).

To elucidate the role of the urotensinergic system, many peptidic and nonpeptidic UT antagonists have been developed over the past decade. Unfortunately, few of them reached the clinical stages, with disappointing results in patients despite promising preclinical results (Vaudry et al., 2015; Castel et al., 2017; Nassour et al., 2019). However, it is possible that limited preclinical studies may not have led to selection of the most appropriate patient population. For instance, palosuran was found ineffective in hypertensive patients with diabetic nephropathy (Vogt et al., 2010) or in patients with type 2 diabetes (Sidharta et al., 2009) despite positive effects on glycated hemoglobin and albuminuria in rat models (Clozel et al., 2004). However, palosuran is now recognized as a very weak antagonist on rodent UT (IC50 > 10 µM), and more selective UT antagonists such as SB-657510 (2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxy-benzenesulfonamide) have been reported to not affect diabetic hyperglycemia (Watson et al., 2013). Therefore, it cannot be excluded that its beneficial effects in rodent models are related to some off-target effects and not to UT blockade. Moreover, no results with selective UT antagonists such as SB-710411 (4-chlorophenyl alanine -c[D-Cys-3-pyridine alanine-D-Trp-Lys-Val-Cys]-4-chlorophenyl alanine -amide) and KR-36996 (N-(1-(3-bromo-4-(piperidin-4-yloxy)benzyl)piper-idin-4-yl)benzo[b]thiophene-3-carboxamide) have been reported in models of CKD, and therefore the use of UT antagonists in this pathology stills remains to be clarified.

To address this question as well as the cardiovascular comorbidities associated with CKD, and thus improve predictivity in clinical studies, SAR101099, a novel potent, orally available, and selective competitive UT antagonist active across species (Altenburger et al., 2008) was extensively studied in this setting. We, here, present a full characterization of its pharmacological properties and therapeutic benefits in multiple models of CKD and CVD, using relevant end points including survival. Results of the phase 1 trials after single or multiple ascending doses indicate a good safety and pharmacokinetics (PK) profile, making this new drug suitable for investigating the role of the urotensinergic system in physiologic and pathologic conditions.

Materials and Methods

Ethical Approvals

Experiments in rats, pigs, and monkeys were performed at Sanofi in AAALAC (Association for Assesssment and Accreditation of Laboratory Animal Care)-accredited facilities in full compliance with the standards for the care and use of laboratory animals, according to French and European Community (Directive 2010/63/EU) legislation. All procedures were approved by the local Animal Ethics Committee (CEEA #24 and CEA#21) and the French Ministry for Research.

The clinical phase I trials complied with recommendations of the 18th World Health Congress (Helsinki, 1964) and all applicable amendments. The protocols also complied with the laws and regulations, as well as any applicable guidelines, in France where the studies were conducted. Informed consents were obtained prior to the conduct of any study-related procedures.

Reagents

Human UII (Bachem AG, Bubendorf, Switzerland), rat and mouse UII (Sigma-Aldrich, St. Louis, MO), and URP (Tocris Biosciences, Bristol, UK) were dissolved in distilled water at 1 mM, and 10-µl aliquots were stored at −20°C until used. Minimum essential medium (MEM) Earle's (1X), gentamicin, and geneticin were from Gibco. Fluo-4 AM (Molecular Devices) was solubilized at 20 mM in DMSO and stored at −20°C until used. Pluronic acid (Molecular Probes) was solubilized at 200 mg/ml in DMSO and stored at −20°C. SAR101099 and palosuran (ACT-058362) were synthesized at Sanofi R&D (Chilly-Mazarin, France). Flashplates PLUS and monoiodinated human [125I-Tyr9]hUII for radioligand binding assays were from PerkinElmer Life Sciences (Boston, MA).

Binding Studies

HEK (human embryonic kidney) -293_hUT-R cells stably expressing the cloned human UT were generated at Sanofi by transfection of HEK-293 with pEAK8-hUT-R construct to assess the affinity of SAR101099 for the human UT. [125I]Tyr9-UII was used as a probe for evaluating the binding characteristics on human UT as previously described (Brkovic et al., 2003). Briefly, cells were incubated with 25 nCi/well [125I-Tyr9]human UII (45 pM) in the presence of increasing concentrations of SAR101099 (1 nM–1 µM) in a total volume of 200 µl of binding assay buffer for 2 hours at + 4°C. After washing the cells with ice-cold PBS, 100 µl of UltimaGold MV mix (PerkinElmer, Waltham, MA) was added for 5 minutes. Bound radioactivity was counted using a MicroBeta counter (PerkinElmer). Total binding was determined in absence of SAR101099, and nonspecific binding was measured in presence of a final concentration of 1 µM of unlabeled UII (n = 2 experiments). The inhibition constant (Ki) was calculated according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973): Ki = IC50/[1 + (radioligand concentration)/Kd].

Geometric mean of Ki values and the respective 95% confidence interval was calculated using BIOST@T-SPEED V2.0 LTS internal application.

Calcium Mobilization Experiments

Chinese hamster ovary (CHO) cells expressing UT were obtained by stably transfecting the human UT (hUT-R, nm_018949), the rat (rUT-R, NM_020597.1), and the mouse (mUT-R, AF441863) into CHO-CRE-Luc-DHFR cells. Transfected cells were seeded in 96-well plates coated with poly-D-lysine (Biocoat; BD) at a density of 4 × 105 cells/well. After 24 hours in culture, cells were rinsed and loaded for 1 hour at 37°C with the calcium dye Fluo-4 AM (10 µM) in the presence of pluronic acid (0.1 mg/ml) in freshly prepared assay medium consisting of Hanks’ balanced salt solution supplemented with HEPES 20 mM, MgSO4 8 mM, Na2CO3 33 mM, CaCl2 10 mM, and bovine serum albumin 1%, pH7.4. Intracellular calcium mobilization experiments were performed at 37° using the fluorometric reader FlipR (Molecular Devices). Fluorescent emissions were recorded simultaneously in all wells at 516 nm following excitation at 494 nm. Serial dilutions of SAR101099 and palosuran were added 10 minutes prior to the addition of agonists: human UII (hUII), rat UII (rUII), mouse UII, or URP, and percent inhibition of UII-induced increase in [Ca] was calculated for each concentration of antagonists. IC50s were calculated using the Sanofi-developed software Biost@t-Speed V2.

Selectivity Profile of SAR101099

An extended profiling of SAR101099 was performed by CEREP on 100 targets (listed in Supplemental Table 1) by using receptor-binding, ion channel–binding, and enzyme assays. The inhibitory action against enzyme activity was assessed either by enzyme immunoassays, fluorimetric, photometric, HTRF (homogeneous time resolved fluorescence), or radiometric assays. The activity of SAR101099 at the 5-HT2B receptors was also determined in an in vitro rat stomach bioassay.

In Vitro Electrophysiology

The effect of SAR101099 (0.04–8.3 µM) on human ether-à-go-go–related gene (hERG) currents was evaluated with the conventional patch-clamp method at room temperature by using whole-cell configuration on CHO cells stably expressing hERG channels, according to a method derived from Yang et al. (2001) and Hamill et al. (1981) with a MultiClamp 700B amplifier along with the eCLAMP software (Molecular Devices Corporation).

SAR101099 electrophysiological effects were also studied in six Purkinje fibers by the microelectrode method (Supplement Methods).

Isolated Rat Aortic Rings

Thoracic aortae from male Lewis rats (n = 8, 12–14 weeks old; Charles River, France) were used to evaluate the competitive antagonist effects of SAR101099 on the contractile response induced by hUII or URP (Supplemental Methods).

Isolated Monkey Coronary and Renal Arteries

Coronary and renal arteries from adult cynomolgus monkeys (n = 4, Macaca Fascicularis, 5 and 6 kg, Noveprim, Mauritius) were obtained following animal euthanasia (Zoletil 50 at 8 mg/kg i.v.). Coronary (circumflex, right and left anterior descending) and renal arteries were collected and cleaned of fat and adhering connective tissue. Endothelium-denuded vessels were cut into circular rings of 2 and 3 mm in length and were manipulated in the same conditions as rat aortic rings except for the addition of 0.01 mmol/l indomethacin in the bathing solution. SAR101099 treatments and calculations are identical to the rat thoracic aorta study.

Hemodynamic Effect of SAR101099

The effect of SAR101099 on mean arterial blood pressure (MAP) was evaluated in rodents, pigs, and nonhuman primates. All hemodynamic data were collected with a telemetry system (Data Sciences International) and analyzed with a HEM software (Notocord systems, France).

Spontaneously hypertensive stroke-prone rat/salt-fat diet.

Male spontaneously hypertensive stroke-prone (SHR-SP) rats (Charles River), 6–8 weeks old, were submitted to a salt-fat diet (SFD) consisting of 1% NaCl supplied in the drinking water and 24.5% fat supplemented in standard NIH-07 diet. Rats were divided into three groups based on body weight and age to receive either the vehicle (control chow NIH-07), SAR101099 at 30 mg/kg per day orally, or ramipril at 3 mg/kg per day orally. To evaluate the pathologic state of SHR-SP rats fed with SFD, age-matched Wistar Kyoto (WKY) normotensive rats (Charles River) were included in the study. This group was not exposed to SFD and was fed with control chow NIH-07 throughout the study. The hemodynamic telemetry monitoring was continuously performed over 24 hours before and after 1, 3, 5, 7, and 9 weeks of treatment. Plasminogen activator inhibitor type 1 (PAI-1) concentrations were determined in plasma by ELISA (Imuclone; American Diagnostica Inc., Greenwitch, CT).

Conscious Telemetered Pig.

A first set of male farm pigs (Cormier, France), weighing between 20 and 30 kg, were prepared to measure the hemodynamic parameters in freely moving animals by using a telemetry device allowing recording of systemic and left ventricular pressure. On the day of the experiment, left ventricular pressure and arterial blood pressure was continuously recorded. Heart rate (HR) was derived from the left ventricular pressure. MAP and maximal value of the first derivative of the left ventricular pressure signal (dP/dtmax) were calculated by HEM software. Each pig was submitted to two experimental sessions, repeated at a 1-week interval. Treatments with SAR101099 (1, 3, or 10 mg/kg po) or its vehicle were given 4 hours before hUII intravenous administration. For each experiment, hemodynamic recording began 2 minutes before the injection of hUII and continued for 15 minutes after dosing.

To confirm these results and to evaluate the duration of action of UTR antagonism by SAR101099, hUII- and URP-induced increase in arterial pressure were measured in a second set of conscious telemetered pigs (same characteristics and provider as above). Each pig was submitted to two experimental sessions performed at 1-week intervals to receive oral treatments with SAR101099A (10 mg/kg) or its vehicle. After each treatment, pigs were assigned to receive either one injection of hUII (0.5μg/kg, i.v., 4 or 8 hours after treatment) or two injections of URP (0.5 μg/kg, i.v., 4 and 8 hours after treatment). The hemodynamic response to hUII or URP was recorded in conscious unrestrained pigs from 2 minutes before to 15 minutes after the injection of hUII and to 10 minutes after the injection of URP.

Telemetered Cynomolgus Monkey.

This study was performed on telemetered male or female cynomolgus monkeys (Macaca Fascicularis, 3.8–9.0 kg; Noveprim, Mauritius). For each monkey, arterial blood pressure (systolic, diastolic, and mean in millimeters of mercury) and HR (in beats per minute) were continuously recorded. The double product (systolic arterial pressure × HR) was calculated and expressed as millimeter of mecury times beats per minute (mm Hg.bpm). In each experimental session, data were collected from at least 2 hours prior to the first administration of SAR101099 (or vehicle) up to 6 hours after the UII challenge. Bolus intravenous injections of SAR101099 (1 mg/kg) and UII (300 ng/kg) were performed in the cephalic or saphenous vein. SAR101099 was administered to animals 1 hour prior to the UII challenge.

Effect of SAR101099 in CKD Models

SHR-SP Rat/SFD.

Male SHR-SP rats (Charles River) were submitted to a high SFD consisting of 1% NaCl supplied in the drinking water and 24.5% fat supplemented in standard NIH-07 diet. They were divided into five groups on the basis of body weight and age to receive either the vehicle, SAR101099 at 30 mg/kg per day po or irbesartan at 10 mg/kg per day, or the combination of both. To evaluate the pathologic state of SHR-SP rats fed with high SFD, age-matched normotensive WKY rats were included in the study. This group was not exposed to the high SFD and was fed with regular standard NIH-07 diet throughout the study. Rats were observed daily to monitor the mortality rate. Animals exhibiting either a decrease of locomotor activity, convulsive movements, paralysis, self-mutilation, or nosebleed were sacrificed, and these rats were included in the mortality rate.

Dahl-Salt Sensitive Rat.

Male Dahl-salt–sensitive (DS) rats (Charles River Laboratories) were placed on a high-salt diet (2% NaCl) supplied by Sniff (Soest, Germany) according to the AIN 76A formula from Dyets Inc. (Bethlehem). Dahl-salt–resistant (DR) sham rat (Charles River Laboratories) received a normal salt diet according to the same formula. The animals were weighed and randomly divided into six groups: four DS groups treated orally either with SAR101099 at 10, 30, or 50 mg/kg per day or irbesartan at 30 mg/kg per day; one DS group receiving vehicle (DS-placebo); and one DR group receiving vehicle. Renal function was evaluated by collecting 24-hour urine in metabolic cages 8 weeks after the beginning of treatment. After collection, urine volumes were measured, and urine aliquots were stored at −20°C after centrifugation. Urine analysis was performed by either a clinical chemistry analyzer (Pentra 400; ABX Diagnostics, France) or ELISA kit. At 8 weeks, creatinine (Jaffé method) and albumin (Rat Albumin Elisa; Bethyl Laboratories) were determined. Rats were observed daily to monitor the mortality rate as described above.

Diabetic Rat.

Male Wistar rats (Charles River Laboratories) were anesthetized with isoflurane 2.5% (AErane; Baxter, France) and then underwent a unilateral nephrectomy to accelerate the development of contralateral nephropathy. After a 2-week recovery period, diabetes was induced by an intravenous injection of streptozotocin (STZ) (65 mg/kg in 1 ml/kg citrate buffer, 10 mM, pH 4.5; Sigma-Aldrich). Sham rats were subjected to unilateral nephrectomy but received the same volume of citrate buffer. Two days after STZ administration, the level of diabetes was determined by serum glucose measurements. Only animals with a hyperglycemia above 17 mmol/l were included in the study. One week after diabetes induction, the chronic oral treatments with compounds or vehicle were initiated for a period of 16 weeks according to a randomization based on serum glucose levels. Two groups received the vehicle (Sham and STZ-placebo), and three other groups received either SAR101099 at 30 or 50 mg/kg per day or irbesartan at 10 mg/kg per day. The last group received the combination of SAR101099 at 30 mg/kg per day and irbesartan at 10 mg/kg per day. The renal function was evaluated as described above after 16 weeks of treatment. Plasma PAI-1 concentrations were determined as described above.

Effect of SAR101099 in Chronic Heart Failure Models

Left Ventricular Dysfunction Post Myocardial Infarction in Rats.

Adult male Lewis rats (260–300 g of body weight; IFFA CREDO, France) were subjected to a permanent left coronary artery ligation as previously described (Selye et al., 1960; Berthonneche et al., 2004) to produce myocardial infarction (MI). The same procedure was performed for sham-operated control animals, but the coronary ligation was not tied. Seven days after coronary ligation, rats were randomly allocated to one of the following five groups: sham-vehicle, MI-vehicle, MI-Ramipril 1 mg/kg per day po, MI-SAR101099 30 mg/kg per day po, or MI-Ramipril 1 mg/kg per day po plus SAR101099 30 mg/kg per day po. Under anesthesia with 2% isoflurane, MAP was measured via a PE-50 arterial catheter inserted into the femoral artery and connected to a pressure transducer (Statham P23XL; Hugo Sacks Electronik, Germany). A second catheter was inserted into the left ventricle (LV) via the right carotid artery to monitor LV systolic pressure, LV end-diastolic pressure (LVEDP), HR, and maximal and minimal values of the first derivative of developed pressure (dP/dtmax and dP/dtmin) as well as to calculate LV developed pressure. To assess the cardiac dysfunction under stress conditions, a PE-10 catheter was inserted into the jugular vein to deliver a continuous infusion of dobutamine at 10 µg/kg per minute for 2 minutes.

After a stabilization period of 20–30 minutes, a 15-minute basal hemodynamic period and cardiac response to dobutamine were recorded and analyzed with a hemodynamic software (IOX 1.8 and Datanalyst; Emka Technologies, France).

Left Ventricular Dysfunction Post Myocardial Infarction in Pig.

The effects of SAR101099 were studied in a pig model of chronic heart failure induced by myocardial infarction. Male farm pigs (Cormier) weighing 22–25 kg were used.

Each pig was submitted to two experimental sessions interspaced by a 7-day period. At day 0, MI was induced after thoracotomy by occluding for 45 minutes the left anterior descending coronary artery below the first diagonal branch followed by reperfusion (IR). The following treatments were given at the onset of reperfusion: SAR101099 (1 mg/kg infused over 20 minutes) (IR-SAR101099 group), its vehicle (methyl pyrrolydon) (IR-vehicle group), or ramipril (0.1 mg/kg) (IR-ramipril group). A sham group receiving the vehicle was used for comparison purposes. Then, during the 7 days following this ischemia/reperfusion episode, animals were daily treated orally either with SAR101099 at 10 mg/kg per day twice a day, ramipril at 1 mg/kg per day, or vehicle. At day 7, cardiac hemodynamics (MAP, HR, dP/dtmax) was performed under anesthesia to evaluate the cardiac function and the inotropic response to dobutamine (intravenous infusion of dobutamine at 1 and 3 µg/kg per minute).

Clinical Trials

Sequential single ascending dose (SAD) by oral administration of SAR101099 from 10 to 500 mg was performed in healthy young men to explore its tolerability, safety, and PK (part 1), before assessing a potential food interaction (food effect, part 2), and to determine the most appropriate conditions of administration for subsequent studies. Tolerability, safety, and PK of SAR101099 was then assessed following multiple ascending oral doses (MAD) from 50 to 500 mg once daily for 14 days in a sequential ascending dose design in healthy young males (Part 3). Detailed study designs are presented in the Supplemental Materials.

Statistical Analysis

Statistical analyses were performed with an in-house software interface accessing SAS system release version 9 and SAS system release 8.2 for SUN4 to carry out the calculations. Results are presented as mean ± S.E.M. in tables and figures. The significance level was set to 0.05 for all analyses. Normality and homogeneity of variance hypotheses were checked with Shapiro-Wilk and Levene tests, respectively. Prior to testing the main hypothesis in each individual in vivo pharmacology study, the vehicle-treated group was compared with the sham-operated group to verify that a noteworthy pathology had indeed been induced in the model. As by definition only two groups were compared, this test was carried out by Student’s t test or else Wilcoxon’s test in case the assumption of normality had to be rejected (*P < 0.05, **P < 0.01, ***P < 0.001). For the actual analysis, SAR101099-treated groups were compared with the appropriate vehicle-treated group. Analyses were carried out by one-way ANOVA unless measurements at repeated time points were available. In this case, repeated-measures ANOVA with time as repeated factor was used. When overall significance was established, Dunnett’s test was used to compare treatments to control or the Bonferroni-Holm method was used for multiple-comparison tests. When the assumption of normality or homogeneity of variance had to be rejected, data were first normalized by Rank transformation or the Kruskal-Wallis test was used (#P < 0.05, ##P < 0.01, ###P < 0.001). The LogRank test was used to analyze survival rate.

Results

UT Affinity and Antagonistic Properties.

SAR101099 (Fig. 1) fully displaced [125I-Tyr9]hU-II binding in a concentration-dependent manner (1 nM–1 µM) with an IC50 of 10.1 nM (Fig. 2A). Using the published Kd value of 1.4 ± 0.2 nM for [125I-Tyr9]hU-II (Brkovic et al., 2003), mean geometric Ki value calculated for SAR101099 was 9.7 nM (2.2–42.9 nM).

Fig. 1.
Fig. 1.

Chemical structure of SAR101099.

Fig. 2.
Fig. 2.

In vitro binding assay of SAR101099 to UII and antagonism assays of SAR10109 and palosuran to human, rat, and mouse UT. (A) SAR101099A displacement curve of [125I]Tyr9-UII binding to human UT. (B) Effects of UII and URP on intracellular calcium mobilization in CHO cells expressing hUT. Mean ± S.E.M. Effects of SAR101099 (C) and palosuran (D) on the intracellular calcium mobilization in CHO cells expressing human, rat, and mouse UT.

Human UII, tested in cultured CHO cells expressing hUT in the concentration range of 3 pM to 1 µM, induced a concentration-dependent increase in fluorescence signal, which returned rapidly to the baseline value with a calculated EC50 of 3.3 nM. The other UT ligand, URP, was tested in the same concentration range as UII and induced an increase in intracellular calcium with an EC50 of 0.96 nM (Fig. 2B). These calcium responses to UII and URP were blocked by SAR101099. To characterize SAR101099 mechanism of action and antagonistic properties at the UT level, its effects were evaluated in CHO cells expressing human or rat or mouse UTs. Palosuran, a highly “primate” UT-selective inhibitor (monkey and human) lacking appreciable affinity at other mammalian UT isoforms (rodent and feline) according to (Behm et al., 2008), was also tested in the same experimental conditions. SAR101099 is a potent competitive antagonist on hUT with an IC50 of 20 nM (15–28 nM) but slightly less active on rat and mouse UT with IC50 values of 67 (53–86 nM( and 97 nM (77–122 nM), respectively. In comparison with SAR101099, palosuran displayed a much lower antagonistic property on hUT with an IC50 of 177 nM (135–231 nM) and very weak activities on UII-induced increase in [Ca2+] mobilization on rat and mouse UT isoforms, with IC50 values of 22 (19–27 µM) and 55 µM (46–68 µM), respectively (Fig. 2, C and D).

In Vitro Selectivity Profile.

When assayed in 100 (mainly human) receptor-binding, ion channel–binding, and enzyme assays, SAR101099, at concentrations up to 10 μM, was inactive (inhibition less than 50%) in most tested targets. It displayed a low affinity to bombesin BB (Ki of 1.5 µM, IC50 of 1.5 μM), histamine H3 (Ki of 1.0 µM, IC50 of 4.1 μM), δ2 (Ki of 7.9 µM, IC50 of 1.3 μM), vasopressin V1a (Ki of 1.7 µM, IC50 of 2.8 μM), and N (neuronal) (α-BGTX/Bungarotoxin-insensitive) (α4β2) (Ki of 1.8 µM, IC50 of 3.6 μM) receptors. All these results demonstrate a good selectivity profile of SAR101099 versus ion channels, G-protein–coupled receptors, enzymes, transporters, and receptor assays and thus a low probability of off-target adverse events.

In Vitro Electrophysiology.

The potential effects of SAR101099 on IKr (Inward rectifier potassium channel) current from hERG channels expressed in stably transfected CHO cells were assessed using the whole-cell patch-clamp method. Based on calculations using the actual concentrations, SAR101099 concentration-dependently blocked hERG currents with a mean IC50 value of 1.2 µmol/l, far from its on-target IC50.

Using a glass microelectrode method, SAR101099 was tested on six rabbit Purkinje fibers at the concentrations of 0.17, 0.75, 2.4, and 10 μmol/l. At 0.17 μmol/l, SAR101099 did not affect resting membrane potential or action potential parameters regardless of the stimulation rate. From 0.75 μmol/l, SAR101099 induced a statistically significant concentration- and reverse-use–dependent increase in action potential duration (APD50 and APD90). At the basal rate of 1 Hz, APD50 was increased by 8% ± 1.6%, 21% ± 3.2%, and 41% ± 6.6%, and APD90 was increased by 9% ± 2.8%, 34% ± 12.4%, and 52% ± 8.3% at 0.75, 2.4, and 10 μmol/l, respectively. The action potential prolongation was reverse-use–dependent; for example, at 2.4 μmol/l, APD90 was increased by 12% ± 1.8%, 34% ± 12.4%, and 68% ± 39.2% at 3, 1, and 0.25 Hz, respectively. Early after depolarizations were observed at 0.25 Hz, in one out of six fibers at 2.4, and 10 μmol/l, which were still observed during the washout period. Whatever the pacing rate, SAR101099 did not alter resting membrane potential, action potential amplitude, or maximal rate of rise of action potential, suggesting that SAR101099 did not act on Na+ channel.

In Vitro Antivasoconstrictor Effects.

Whereas the contractile response of rat aorta to KCl was rapid and quickly reversible, the contraction elicited by hUII or URP was slow-appearing and long-lasting, reaching its maximum 30 minutes or more after application and was irreversible. Results of experiments indicated a very similar potency of both UII and URP agonists with respective EC50 values of 1.40 and 1.45 nM (data not shown). The pretreatment of rat aortic rings with SAR101099 (0.1–10 µM) over 30 minutes did not affect the basal tension, suggesting that the compound is devoid of any intrinsic activity in this tissue. Exposure of rat isolated aortic rings to SAR101099 (0.1–10 µM) resulted in concentration-dependent, rightward, parallel shifts in the hUII and URP concentration-response curves (Fig. 3, A and C). Maximal contractile responses remained unaltered (107%–118% and 86%–108% KCl response, respectively), showing that this inhibition was surmountable. Global nonlinear regression analysis gave equipotent pKb (negative logarithm of the dissociation constant) of 7.2 (7.0; 7.4) and 7.1 (6.9; 7.3), respectively (Fig. 3, B and D).

Fig. 3.
Fig. 3.

In vitro antivasoconstrictor effects of SAR101099. Effect of increasing concentrations of SAR101099 (0.1–10 µM) on the concentration-response curves of hUII (A) and URP (C) in isolated rat thoracic aorta and in isolated coronary (E) and renal (F) monkey arteries. Results are expressed as mean ± S.E.M. (KCl response taken as 100%) obtained from n = 4–8 preparations in rat aorta, from n = 8–13 monkey coronary, and from n = 3–5 monkey renal arteries. Shild-plot on UII (B) and on URP (D) responses in rat are depicted as an example.

Given the high homology of the urotensinergic system between the monkey and human and to further characterize these properties and improve the translatability/predictivity of preclinical results, the antivasoconstrictor properties were also tested in monkey arteries coming from different vascular beds. Exposure of monkey isolated coronary and renal arteries to increasing concentrations of hUII resulted in a potent and sustained concentration-dependent contraction. Calculated EC50 values were 0.016 nM (0.006–0.041 nM) for coronary artery and 0.188 nM (0.079–0.447 nM) for renal artery with Emax (maximal effect) values of 146% and 77%, respectively, when normalized to KCl-induced contraction (Fig. 3, E and F). A 30-minute pretreatment of monkey arteries with SAR101099 (0.3–3 μM) did not affect basal tension but resulted in a concentration-dependent, rightward, and parallel shift in the hUII concentration-response curve (Fig. 3, E and F). Maximal contractile responses remained unaltered in coronary and renal arteries (146%–162% and 77%–113% of KCl response, respectively). Global nonlinear regression analysis gave a pKb of 7.7 (7.3–8.2) in coronary arteries and 7.4 (7.3–7.4) in renal arteries.

Hemodynamic Profile.

These antivasoconstrictor properties were then investigated in conscious animals from various species to minimize the risk of bias because of a specific model and improve the translatability/predictivity to humans.

For hemodynamic investigations in rats, SHR-SP rats under SFD were selected because this regimen was known to aggravate hypertension and to accelerate the progression of CKD in this strain, making this model attractive to explore potential blood pressure–lowering effects of UT antagonists in comparison with renin-angiotensin-aldosterone system (RAAS) inhibitors reported for their efficacy in this setting (Abrahamsen et al., 2002). Arterial blood pressure and HR were therefore determined before and after 1, 3, 5, 7, and 9 weeks of SAR101099 treatment (30 mg/kg per day, orally) or ramipril (3 mg/kg per day, orally) in conscious freely moving rats. SHR-SP rats on SFD diet had a significantly higher blood pressure than normotensive WKY rats (Fig. 4A), without modification of HR (data not shown). SAR101099 did not lower arterial pressure but rather blunted the progression of hypertension induced by SFD, whereas ramipril 3 mg/kg significantly reduced the hypertension (Fig. 4A).

Fig. 4.
Fig. 4.

Hemodynamics effects of orally administered SAR101099 in conscious rats, pigs, and monkeys. Mean ± S.E.M. arterial blood pressure in SHR rat in which hypertension was induced by salt-fat diet (A), in pigs in which hypertension was induced by hUII (B and C) or by URP before SAR101099 treatment (D). (E) Mean ± S.E.M. arterial blood pressure and (F) mean ± S.E.M. heart rate in monkeys in which hypertension was induced by hUII before SAR101099 treatment.

Because of the similarities between pig and human hearts, pigs are considered good models to improve the translatability to the human cardiovascular responses. However, existing reports show substantial variability in the effects of UII in isolated pig vessels (Douglas et al., 2000; Camarda et al., 2002). It therefore appeared important to characterize the hemodynamic effects of UII and its cognate receptor antagonist in conscious animals before carrying out heart failure studies with UT antagonist. In conscious telemetered pigs, intravenous injection of hUII (0.5 µg/kg i.v.) significantly increased MAP without affecting HR. These hemodynamic effects lasted at least 15 minutes before returning to baseline. They were significantly and dose-dependently inhibited by SAR101099 administered orally 4 hours before hUII injection. SAR101099 10 mg/kg fully antagonized the pressor response to hUII (Fig. 4B). This effect was confirmed in a second set of pigs in which hUII or URP (0.5 µg/kg, i.v.) were administered 4 or even 8 hours after oral SAR101099 treatment at 10 mg/kg (study 3), showing a full inhibition of hUII and URP pressor effects and highlighting the long duration of action of SAR101099 (Fig. 4, C and D).

No effect on HR was observed after SAR101099 administration (data not shown) in any of the studies performed in conscious rat or pigs.

Responses of telemetered cynomolgus monkey were also studied because of their major translational relevance and the dramatic cardiovascular collapse that UII has previously been reported to induce in this species (Zhu et al., 2004). Handling of conscious monkeys in restraining conditions to allow intravenous injections induced significant hemodynamic changes consisting of a marked and sudden increase in heart rate (from 132 to 222 bpm) and blood pressure (from 99 to 116 mm Hg). These modifications were sustained and not reversed during the 15 minutes following injection (Fig. 4, E and F, vehicle/saline group). In these conditions, the UII challenge (0.3 µg/kg, i.v.) induced a dramatic myocardial depression with a marked decrease in HR and blood pressure. The maximum decrease in blood pressure occurred 10 minutes postinjection from 105 mm Hg in the control group to 69 mm Hg in the UII group and remained low during the period of recording (Fig. 4E, vehicle/UII group). The maximum decrease in HR occurred 5 minutes postinjection, with a drop from 207 bmp in the vehicle/saline group to 135 bpm in the UII group, but returned to control value at 15 minutes (Fig. 4F, vehicle/UII group). SAR101099 pretreatment, 1 hour prior to the U-II challenge, prevented both the decrease in blood pressure and HR (Fig. 4, E and F, 1 mg/kg/UII group). The maximal heart rate decrease observed 5 minutes after U-II injection (135 bpm) was reverted to 174 bpm at 15 minutes. In the presence of SAR101099, no drop in blood pressure was observed during the recording period. No gender effect was noted during the study. In one nonhuman primate whose results were excluded from the study, hUII produced a dramatic myocardial depression, eventually evoking a life-threatening cardiovascular collapse, which was rescued by an intravenous administration of SAR101099 at 1 mg/kg (Supplemental Fig. 1).

Chronic Kidney Disease.

Harmful effects of SFD on CKD progression in SHR-SP rats have been well documented in the literature (Abrahamsen et al., 2002). SHR-SP rats fed with SFD developed a severe and progressive proteinuria 8.7-fold higher (P < 0.0001) than WKY rats at 8 weeks (Fig. 5A). Chronic treatment with SAR101099 (30 mg/kg per day) for 8 weeks prevented the rise in proteinuria compared with the SHR-SP SFD-vehicle group (−50%, P = 0.0455). The ramipril-treated group (3 mg/kg per day) also displayed a significant reduction in proteinuria compared with the SHR-SP SFD-vehicle group (−79%, P < 0.0001). In comparison with WKY rats, SHR-SP rats on SFD had severe glomerular and tubulointerstitial lesions, including glomerulosclerosis, as well as renal arteriolar damage. SAR101099 treatment tended to reduce the severity of renal arteriolar lesions (score: −18%, P = 0.0504) (Fig. 5B). The chronic treatment with ramipril limited both glomerular injury (−90%, P < 0.05) and the severity of renal arteriolar lesions (−35%, P < 0.01), which was also in line with the reduction observed in proteinuria in this group. Both compounds significantly prevented the rise of PAI-1, a marker of inflammation and fibrosis (Ma and Fogo, 2009), induced by the pathology (Supplemental Fig. 3).

Fig. 5.
Fig. 5.

SAR101099 effect in different rat models of renal impairment. (A) Mean + S.E.M. proteinuria after 8 weeks of treatment in SHR-SP fed with salt-fat diet rat model. (B) Mean + S.E.M. score of arteriolar lesion severity in SHR-SP salt-fat diet rat model. (C) Mean + S.E.M. albuminuria/creatininuria ratio after 8 weeks of treatment in Dahl-salt–sensitive rat model. (D) Mean +S.E.M. albuminuria after 16 weeks of treatment in STZ rat with unilateral nephrectomy.

To assess the renal protective effect of UT antagonist in a CKD model of a different hypertensive etiology than SHR-SP SFD (Rapp, 2000; Schulz and Kreutz, 2012), SAR101099 was tested in DS rats, which are exceptionally prone to develop renal dysfunction, particularly under a high-salt diet. As expected, DS rats submitted to high-salt diet displayed a dramatic increase in urinary albumin-to-creatinine ratio when compared with DR rats (7.60 ± 1.06 versus 0.69 ± 0.27 mg/μmol, P < 0.0001, respectively). Chronic treatment of SAR101099 administered at 10, 30, or 50 mg/kg per day for 8 weeks reduced significantly the albumin-to-creatinine ratio in comparison with DS rat receiving the vehicle [4.70 ± 0.56 (P = 0.0266), 4.61 ± 0.78 (P = 0.0157), and 4.45 ± 0.67 (P = 0.0075) versus 7.60 ± 1.06 mg/μmol, respectively]. In comparison, irbesartan provided similar beneficial effects on this parameter (Fig. 5C). This positive effect of SAR101099 on renal dysfunction was independent of any blood pressure change (Fig. 4A).

Although both the SHR-SP and DS rats suffer from metabolic alterations (Schulz and Kreutz, 2012), it was important to additionally investigate the effects of UT antagonist in a CKD model of diabetic origin (Hewitson et al., 2009). In rats in which diabetic nephropathy was induced by unilateral nephrectomy and STZ, the urinary albumin excretion was dramatically increased in the STZ group in comparison with the sham group. SAR101099 at 50 mg/kg significantly reduced the STZ-induced albuminuria. Irbesartan administered alone or in combination with SAR101099 did not significantly improve renal function (Fig. 5D).

SAR101099 significantly and consistently improved the renal function in these different models without modifying either metabolism (glucose, cholesterol, triglycerides, body weight) or hemodynamic parameters (MAP and heart rate).

Survival in CKD Models.

The translation of renal function improvement into increase of survival rate has been evaluated in different rat models.

SHR-SP rats fed with SFD suffer from CKD but also from cardiac hypertrophy (Barone et al., 1996), suggesting that they share some of the cardiac complications observed in CKD patients. As such, they displayed a high mortality rate of 59.4% by 29 weeks, which differed significantly from the normotensive WKY rats (P = 0.003). Chronic administration of SAR101099 alone or in combination with irbesartan significantly improved survival (P = 0.0338 and P < 0.0001, respectively). Chronic administration of irbesartan alone markedly and significantly reduced the mortality rate (P < 0.0001) (Fig. 6A).

Fig. 6.
Fig. 6.

Survival improvement in rat models of renal impairment. (A) SHR-SP salt-fat diet rat model. (B) Dahl-salt–sensitive rat model.

In a CKD model with different etiology, the Dahl-salt–sensitive rat model, in which hypertension is the predominant pathogenic factor (Rapp, 2000; Schulz and Kreutz, 2012), a mortality rate of 45% was noted in DS-vehicle group. Without reaching a statistically significant level, SAR101099 at 10, 30, and 50 mg/kg tended to improve the survival rate in comparison with the DS-vehicle–treated group in a dose-dependent manner, with 30%, 25%, and 16% versus 45% of mortality, respectively. Irbesartan 10 mg/kg orally significantly improved the survival rate (95%) in comparison with DS-vehicle group (P = 0.0193) (Fig. 6B).

Effect of SAR101099 in Chronic Heart Failure Models.

Because the urotensinergic system is widely expressed in the cardiovascular system, and CKD patients die mainly from cardiovascular complications, we investigated the potential benefits of SAR101099 effects in various models of heart failure in comparison or on top of standard of care, namely, an ACE inhibitor or an AT1 receptor blocker.

SAR101099 was first evaluated in a rat model of heart failure induced by MI. MI induced a marked dilatation of the left ventricle with a 213% increase in ventricular cavity surface area in the MI-vehicle group compared with the sham-operated group. However, SAR101099 or ramipril or the combination of both had no effect on infarct size (data not shown) or cardiac remodeling. The mean surface area of left ventricular cavity was similar to the MI-vehicle group (from 30.2 to 32.5 mm2) whatever the treatments. Without altering MAP (Fig. 7A), 7 days after MI, SAR101099 significantly preserved the cardiac contractile reserve as depicted in Fig. 7B. SAR101099 also significantly reduced the rise in LVEDP induced by MI from 14.5 ± 1.7 mm Hg in the MI-vehicle group to 8.9 ± 1 mm Hg in the MI-SAR101099 group (Fig. 7C).

Fig. 7.
Fig. 7.

Effect of SAR101099 in chronic heart failure models. (A–C) Mean + S.E.M. MAP, LVEDP, and dP/dtmax measured in rat model. (D and E) Mean S.E.M. + MAP and dP/dtmax measured in pig model of left ventricular dysfunction post-MI.

The same effect on cardiac contractile reserve was observed in another model of chronic heart failure developed in pigs, which develop contractile and biochemical alterations more similar to those observed in humans (Milani-Nejad and Janssen, 2014). Seven days after ischemia/reperfusion injury in pigs, the cardiac function was significantly depressed, as supported by the decrease in MAP and cardiac contractility (measured by dP/dtmax) in the MI-vehicle group as compared with sham-operated group (−17% and −18%, respectively). MI led to a decrease in MAP, which was not modified by any of the treatments (Fig. 7D). Repeated administration of SAR101099 initiated at the onset of reperfusion improved the cardiac contractile reserve in pigs as assessed by the dobutamine response (Fig. 7E, P = 0.041 at 1 µg/kg and P = 0.057 at 3 µg/kg of dobutamine), whereas ramipril had no effect (P = 0.10 and P = 0.14 at 1 and 3 µg/kg of dobutamine). Neither of the drugs tested had an effect on infarct size.

Clinical Trials.

During the SAD study, no adverse events were observed. A few treatment-emergent adverse events without any specific pattern and no clinically significant abnormalities in biologic tests and vital sign parameters were reported across dose groups (Supplemental Table 2). Regarding ECG evaluation, no clinically significant abnormalities were reported.

SAR101099 was rapidly absorbed after a single oral administration of 10–500 mg. Elimination was characterized by an apparent elimination half-life (∼12 hours) regardless of dose. Exposure increased in a dose proportional manner between 10 and 500 mg but more than dose proportionally between 200 and 400 mg (Supplemental Table 3).

After repeated oral daily administration of SAR101099 from 50 to 500 mg for 14 days (MAD study), less than 1.3-fold accumulation of exposure was observed after 2 weeks of treatment (Fig. 8). SAR101099 was generally absorbed with median tmax (time to maximal concentration) of 2–4 hours whatever the dose and the day. No deviation from dose proportionality was observed for Cmax (maximal concentration) and AUC0-24 on day 14; for a 10-fold increase in dose from 50 to 500 mg, Cmax increased by 9.9-fold (90% CI: 9.26–12.22 and 8.34–11.64) and AUC0-24 by 10.2-fold (90% CI: 8.68–11.96) (Supplemental Table 4). No significant effect of dose on terminal half-life was shown across the dose range, with a geometric mean estimated terminal half-life of 14.3 hours (90% CI: 13.45–15.23) for pooled doses. Overall, the within-subject variability of blood PK parameters (Cmax and AUC0-24) was low (estimates of within-subject CV = 14% and 11%, respectively).

Fig. 8.
Fig. 8.

Mean + S.D. SAR101099 blood concentration-time profiles on day 1 and day 14 over a 24-hour period in linear scale.

There was one severe adverse event in this study, a tendinoplasty, not related to the study drug administration and one drop out because of an increased CPK following a trauma on one arm. A good overall safety/tolerability was observed at all doses of SAR101099 50, 130, 260, 350, and 500 mg once a day for 14 days. No clinically relevant abnormalities were issued from laboratory tests and vital sign evaluations, including the hemodynamic parameters (Supplemental Table 5). Regarding ECG evaluation, there was no individual clinically significant abnormality in any parameter. A mean elevation of QTcF (QT interval corrected according to Fridericia's formula) from time-matched baseline was observed at 260 mg and above. No relevant changes were observed on ECG morphology or on mean values of HR, QRS, or PR intervals in any dose group.

Overall, the safety and tolerability profile of SAR101099 in the SAD or MAD studies conducted in healthy young male subjects was considered acceptable. In addition, after a single administration, no relevant effect of food was observed on SAR101099 PK parameters.

Discussion

Despite high unmet medical need in chronic kidney disease (CKD), few drug candidates are in clinical development today. This is mainly due to a high failure rate in phase 3 trials, which were unable to demonstrate an improvement in renal outcomes and associated cardiovascular risk, and to an incomplete understanding of human disease biology as well as a poor translatability of the preclinical studies that often did not sufficiently consider the cardiovascular comorbidities driving mortality in CKD patients.

The present report describes a novel, potent, nonpeptidic UT antagonist, SAR101099, that displays a good selectivity and safety profile and is orally active and long-acting. Its in vivo efficacy is demonstrated both in chronic renal and in cardiac dysfunction models developed in various preclinical species to improve its predictivity of clinical efficacy in humans.

Several nonpeptidic antagonists have already been reported in the literature but often with a profile limited to their UII pattern blockade. Here, we show that SAR101099 consistently antagonized UT activation induced by UII or UPR both in vitro and in vivo in various species or animal models. Compared with other UT antagonists, it shows a high binding affinity with an Ki of 9.7 nM and consistent ability to antagonize urotensin-induced vasoconstriction of isolated rat, pig, and nonhuman primate arteries, with pKb values in the range of 7.2–7.7, making it a best-in-class compound across species.

The poor selectivity profile of other nonpeptidic UT antagonists may explain why only a few drug candidates entered clinical development. SAR101099 was selected for its UT selectivity, as it showed no relevant binding activity to a large panel of receptors, ion channels, and enzymes (less than 50%) at concentrations up to 10 µM. Only a low binding affinity to bombesin, histamine H3, V1a, and N (neuronal) (α-BGTX-insensitive) (α4β2) was reported but with no functional activity. This differs from palosuran, which has been shown to display significant off-target activity, thus compromising the relevance of solely blocking UT in the interpretation of the preclinical and clinical studies reported (Strowski et al., 2006; Malagon et al., 2008).

Although UII does not alter blood pressure in rodents, it caused a significant hypertensive effect in conscious pigs. SAR101099 at 10 mg/kg orally completely blocked the pressure response to both UII and URP up to 8 hours post-treatment, highlighting the attractive properties of SAR101099 as a long-acting UT antagonist. In comparison, SAR101099 at 1 mg/kg orally was more potent and long-lasting at blocking the pressor response to UII in pigs than SB611812 (2,6-dichloro-N-(4-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-4-(trifluoromethyl)benzenesulfonamide), another UT antagonist (Supplemental Fig. 2 ). No effect on heart rate was observed at pharmacological active doses in rodents and pigs. Interestingly, in one monkey in which UII at 0.3 µg/kg i.v. induced a severe cardiovascular collapse likely related to a profound coronary vasoconstriction [also described by Zhu et al. (2004)], intravenous administration of SAR101099 at 1 mg/kg allowed to rescue the animal from dying with a prompt and full restoration of the hemodynamics (Supplemental Fig. 1 ). Taken together, the results across the different species show a consistent UT antagonist profile of SAR101099 despite diverging effects of UII. The UT antagonist SAR101099 has no effect on blood pressure but is able to inhibit any UII responses that can be elicited, suggesting that SAR101099 should be able to consistently reduce all pathologic processes related to UT activation. These results also underline the attractive safety profile of the drug, making its administration suitable on top of the current standard of care with a good hemodynamic tolerance expected.

The extensive evaluation of SAR101099 in different models of chronic renal and cardiac impairment demonstrates that it is a potent UT antagonist devoid of species selectivity. The chronic CKD studies confirmed its strong renoprotective effect with a marked reduction in proteinuria, renal arteriole damage, and inflammation whether the pathology was mainly induced by hypertension (DS rats), diabetes (STZ rats), or both (SHR-SP on SFD) and at doses that do not lower blood pressure. This latter point is critical because CKD trials have to be conducted on top of standard of care, including RAAS inhibitors known for their antihypertensive and hemodynamic effects. That is why future treatments for CKD beyond renal protection should have limited impact on blood pressure to reduce the risk of renal hypoperfusion and hypotension. Interestingly, angiotensin II increased UII and UT expression in tubular cells, and UII interacts in synergy with angiotensin II. UII gene polymorphism has been also associated with some renal diseases and could be considered to streamline more relevant CKD patient populations for UT blockade (Balat and Buyukcelik, 2012).

CKD translation from animals to humans is, however, challenging because RAAS is recognized as the main contributor in the pathogenesis of CKD in rodents. RAAS inhibition markedly suppresses proteinuria and improves survival in various CKD models but mainly at doses that lower blood pressure. In contrast, although ACEi (ACE inhibitor)/ARB treatments reduce proteinuria in patients, they do not halt progression toward end-stage renal disease. Ravera et al. (2005) showed in the PRIME (PRogram for Irbesartan Mortality and morbidity Evaluation) study that neither irbesartan (ARB) nor amlopidine (calcium channel blocker) provide total protection from both renal and cardiovascular events in patients; however, for instance in SHR-SP submitted to SFD, irbesartan notably suppressed proteinuria and decreased the mortality rate in this rodent model (Supplemental Fig. 4, A and B).

The benefit of chronic treatment with SAR101099 on long-term survival in rat models at doses from 30 to 50 mg/kg per day orally deserves special attention. Because no metabolism changes were observed in the different studies (cholesterol, glucose, triglycerides, body weight), and because of the potency and selectivity profile of SAR101099, we can hypothesize that this improvement is mainly driven by UT antagonism. In opposition, the 25% survival improvement observed by Clozel et al. (2006) in a STZ-induced diabetes rat model with palosuran at 300 mg/kg per day [a dose known to prevent the development of renal failure (Clozel et al., 2004)] is difficult to interpret because, at that dose, an off-target effect toward somatostatin receptors that are involved in the glucose and albuminuria regulation has previously been demonstrated (Strowski et al., 2006; Malagon et al., 2008). If the improvement is driven by the positive change in metabolism, that might explain why these positive results were not reproduced in patients with type 2 diabetes and nephropathy.

In addition, because CKD patients mostly die from CVD complications, it was important to evaluate the benefit of SAR101099 on cardiac outcomes. In rat and pig models of chronic heart failure, SAR101099 restored both the impaired contractile state as well the cardiac contractile reserve, i.e., the capability to adequately respond to inotropic support (dobutamine) together with a reduction in left ventricular filling pressure. The positive effects of SAR101099 in pigs are particularly interesting because RAAS inhibition with ramipril was much less beneficial than in rats, consistent with its limited protective effect in human CKD patients with heart failure (Lunney et al., 2020).

The results of phase I trials (SAD, MAD, and food effect studies) confirmed the safe profile of SAR101099 in young heathy male subjects with PK properties suitable for clinical development. Following repeated once daily oral administration of SAR101099, less than 1.3-fold accumulation was observed after 2 weeks of treatment. On day 14, SAR101099 exposure increased in proportion with the dose between 50 and 500 mg. The within- and between-subject variability was limited, and no notable food effect was observed. As of today, no clinical study has yet been conducted in CKD patients. The present data suggest that it will be important to confirm the promising preclinical data in CKD patients.

One particular challenge of the CKD indication is that the disease suffers from a large heterogeneity with subpopulations progressing at different rates regardless of the etiology and level of proteinuria. Diabetes-independent factors can cause CKD, even in patients with diabetes (Anders et al., 2018). New approaches for segmenting CKD, such as deep phenotyping, may be needed to subsequently facilitate specific investigations of the underlying mechanisms that contribute to disease progression or cardiovascular complications in the different subgroups, allowing more targeted therapies and improved CKD patient management. Several approaches have been initiated to better characterize the natural history of this heterogenous pathology, improve its diagnosis, identify the genetic factors involved (Levin et al., 2017), or better stratify the CKD patients using artificial intelligence (Elhoseny et al., 2019). The present data suggest that urotensinergic activity should be one of the parameters to be included in this analysis.

Altogether these preclinical and clinical results suggest that UT antagonism remains an attractive target in CKD on top of current standard of care. UT blockade is neutral on hemodynamics, which would limit the risk of an additional blood-pressure–lowering effect when combined with ACEi or ARBs. A selective long-lasting UT blockade with drugs such as SAR101099 could address complementary pathogenic pathway for the benefit of CKD patient subgroups, which today remain to be defined. Its unique pharmacological properties, selectivity, PK, and safety profiles offer new avenues for better appreciating the role of the urotensinergic system in CKD patients.

Acknowledgments

We acknowledge expert technical assistance of Brigitte Dubreuil, Corinne Gomez, Laetitia Bernard, Chrystelle Battut, and Fiona Ducrey.

Authorship Contributions

Participated in research design: Briand, Pelat, Beauverger, Poirier, Petit, Altenburger, Janiak.

Conducted experiments: Briand, Pelat, Barbe, Poirier, Guillon, Bidouard.

Contributed new reagents or analytic tools: Petit, Altenburger.

Performed data analysis: Briand, Pelat, Beauverger, Guillon, Bidouard, Janiak.

Wrote or contributed to the writing of the manuscript: Ozoux, Briand, Pelat, Schaeffer, Guillon, Bidouard, Janiak.

Footnotes

Abbreviations

ACE
angiotensin-converting enzyme
APD
action potential duration
ARB
angiotensin II receptor blocker
CHO
Chinese hamster ovary
CKD
chronic kidney disease
CVD
cardiovascular disease
DR
Dahl-salt resistant
DS
Dahl-salt sensitive
hERG
human ether-à-go-go–related gene
HR
heart rate
Kd
dissociation constant
Ki
inhibition constant
LV
left ventricle
LVEDP
LV end-diastolic pressure
MAD
multiple ascending dose
MAP
mean arterial blood pressure
MI
myocardial infarction
PAI-1
plasminogen activator inhibitor type 1
PK
pharmacokinetics
RAAS
renin-angiotensin-aldosterone system
SAD
single ascending dose
SAR101099
1-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-(2-methylphenyl)pyridin-2-yl]carbonyl}amino) cyclohexanecarboxylic acid hydrochloride
SFD
salt-fat diet
SHR-SP
stroke-prone spontaneously hypertensive rat
STZ
streptozotocin
UII
urotensin II
URP
urotensin-related peptide
UT
urotensin II receptor
WKY
Wistar Kyoto

This is an open access article distributed under the CC BY-NC Attribution 4.0 International license.

References

  1. ↵
    1. Abrahamsen CT,
    2. Barone FC,
    3. Campbell WG Jr..,
    4. Nelson AH,
    5. Contino LC,
    6. Pullen MA,
    7. Grygielko ET,
    8. Edwards RM,
    9. Laping NJ, and
    10. Brooks DP
    (2002) The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. J Pharmacol Exp Ther 301:21–28.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Altenburger J-M,
    2. Fossey V,
    3. Janiak P,
    4. Lassalle G,
    5. Petit F, and
    6. Vernières J-C
    (2008) inventors, Sanofi Aventis, assignee. 5,6-Bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists. 21/02/2008 Patent WO 2008/020124 A1.
  3. ↵
    1. Ames RS,
    2. Sarau HM,
    3. Chambers JK,
    4. Willette RN,
    5. Aiyar NV,
    6. Romanic AM,
    7. Louden CS,
    8. Foley JJ,
    9. Sauermelch CF,
    10. Coatney RW, et al.
    (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282–286.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Anavekar NS,
    2. McMurray JJV,
    3. Velazquez EJ,
    4. Solomon SD,
    5. Kober L,
    6. Rouleau J-L,
    7. White HD,
    8. Nordlander R,
    9. Maggioni A,
    10. Dickstein K, et al.
    (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285–1295.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Anders HJ,
    2. Huber TB,
    3. Isermann B, and
    4. Schiffer M
    (2018) CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol 14:361–377.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Balat A and
    2. Büyükçelik M
    (2012) Urotensin-II: more than a mediator for kidney. Int J Nephrol 2012:249790.
    OpenUrlPubMed
  7. ↵
    1. Barone FC,
    2. Nelson AH,
    3. Ohlstein EH,
    4. Willette RN,
    5. Sealey JE,
    6. Laragh JH,
    7. Campbell WG Jr.., and
    8. Feuerstein GZ
    (1996) Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 279:948–955.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Behm DJ,
    2. Doe CPA,
    3. Johns DG,
    4. Maniscalco K,
    5. Stankus GP,
    6. Wibberley A,
    7. Willette RN, and
    8. Douglas SA
    (2004) Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 369:274–280.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Behm DJ,
    2. McAtee JJ,
    3. Dodson JW,
    4. Neeb MJ,
    5. Fries HE,
    6. Evans CA,
    7. Hernandez RR,
    8. Hoffman KD,
    9. Harrison SM,
    10. Lai JM, et al.
    (2008) Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br J Pharmacol 155:374–386.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Berthonneche C,
    2. Sulpice T,
    3. Boucher F,
    4. Gouraud L,
    5. de Leiris J,
    6. O’Connor SE,
    7. Herbert JM, and
    8. Janiak P
    (2004) New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol 287:H340–H350.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bousette N and
    2. Giaid A
    (2006) Urotensin-II and cardiovascular diseases. Curr Hypertens Rep 8:479–483.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Brkovic A,
    2. Hattenberger A,
    3. Kostenis E,
    4. Klabunde T,
    5. Flohr S,
    6. Kurz M,
    7. Bourgault S, and
    8. Fournier A
    (2003) Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J Pharmacol Exp Ther 306:1200–1209.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Camarda V,
    2. Rizzi A,
    3. Calò G,
    4. Gendron G,
    5. Perron SI,
    6. Kostenis E,
    7. Zamboni P,
    8. Mascoli F, and
    9. Regoli D
    (2002) Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365:141–149.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Castel H,
    2. Desrues L,
    3. Joubert JE,
    4. Tonon MC,
    5. Prézeau L,
    6. Chabbert M,
    7. Morin F, and
    8. Gandolfo P
    (2017) The G protein-coupled receptor UT of the neuropeptide urotensin II displays structural and functional chemokine features. Front Endocrinol (Lausanne) 8:76.
    OpenUrl
  15. ↵
    1. Cheng Y and
    2. Prusoff WH
    (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Clozel M,
    2. Binkert C,
    3. Birker-Robaczewska M,
    4. Boukhadra C,
    5. Ding S-S,
    6. Fischli W,
    7. Hess P,
    8. Mathys B,
    9. Morrison K,
    10. Müller C, et al.
    (2004) Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. J Pharmacol Exp Ther 311:204–212.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Clozel M,
    2. Hess P,
    3. Qiu C,
    4. Ding SS, and
    5. Rey M
    (2006) The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316:1115–1121.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Conlon JM,
    2. Yano K,
    3. Waugh D, and
    4. Hazon N
    (1996) Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 275:226–238.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Coulouarn Y,
    2. Jégou S,
    3. Tostivint H,
    4. Vaudry H, and
    5. Lihrmann I
    (1999) Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 457:28–32.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Douglas SA,
    2. Sulpizio AC,
    3. Piercy V,
    4. Sarau HM,
    5. Ames RS,
    6. Aiyar NV,
    7. Ohlstein EH, and
    8. Willette RN
    (2000) Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131:1262–1274.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Douglas SA,
    2. Tayara L,
    3. Ohlstein EH,
    4. Halawa N, and
    5. Giaid A
    (2002) Congestive heart failure and expression of myocardial urotensin II. Lancet 359:1990–1997.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Elhoseny M,
    2. Shankar K, and
    3. Uthayakumar J
    (2019) Intelligent diagnostic prediction and classification system for chronic kidney disease. Sci Rep 9:9583.
    OpenUrl
  23. ↵
    1. Eyre HJ,
    2. Speight T,
    3. Glazier JD,
    4. Smith DM, and
    5. Ashton N
    (2019) Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat. Exp Physiol 104:421–433.
    OpenUrl
  24. ↵
    1. Gardiner SM,
    2. March JE,
    3. Kemp PA,
    4. Davenport AP, and
    5. Bennett T
    (2001) Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132:1625–1629.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Gruson D,
    2. Rousseau MF,
    3. Ketelslegers J-M, and
    4. Hermans MP
    (2010) Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 12:653–660.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Hamill OP,
    2. Marty A,
    3. Neher E,
    4. Sakmann B, and
    5. Sigworth FJ
    (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85–100.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Hewitson TD,
    2. Ono T, and
    3. Becker GJ
    (2009) Small animal models of kidney disease: a review. Methods Mol Biol 466:41–57.
    OpenUrlPubMed
  28. ↵
    1. Langham RG,
    2. Kelly DJ,
    3. Gow RM,
    4. Zhang Y,
    5. Dowling JK,
    6. Thomson NM, and
    7. Gilbert RE
    (2004) Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44:826–831.
    OpenUrlCrossRefPubMed
    1. Lees JS,
    2. Welsh CE,
    3. Celis-Morales CA,
    4. Mackay D,
    5. Lewsey J,
    6. Gray SR,
    7. Lyall DM,
    8. Cleland JG,
    9. Gill JMR,
    10. Jhund PS, et al.
    (2019) Glomerular filtration rate by differing measures, albuminuria and prediction of vascular disease, mortality and end-stage kidney disease. Nature Medicine 25:1753–1760.
    OpenUrl
  30. ↵
    1. Levin A,
    2. Tonelli M,
    3. Bonventre J,
    4. Coresh J,
    5. Donner JA,
    6. Fogo AB,
    7. Fox CS,
    8. Gansevoort RT,
    9. Heerspink HJL,
    10. Jardine M, et al., and ISN Global Kidney Health Summit participants
    (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390:1888–1917.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Lunney M,
    2. Ruospo M,
    3. Natale P,
    4. Quinn RR,
    5. Ronksley PE,
    6. Konstantinidis I,
    7. Palmer SC,
    8. Tonelli M,
    9. Strippoli GF, and
    10. Ravani P
    (2020) Pharmacological interventions for heart failure in people with chronic kidney disease. Cochrane Database Syst Rev 2:CD012466.
    OpenUrl
  32. ↵
    1. Luyckx VA,
    2. Tonelli M, and
    3. Stanifer JW
    (2018) The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 96:414–422D.
    OpenUrlPubMed
  33. ↵
    1. Ma LJ and
    2. Fogo AB
    (2009) PAI-1 and kidney fibrosis. Front Biosci 14:2028–2041.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Malagon MM,
    2. Molina M,
    3. Gahete MD,
    4. Duran-Prado M,
    5. Martinez-Fuentes AJ,
    6. Alcain FJ,
    7. Tonon MC,
    8. Leprince J,
    9. Vaudry H,
    10. Castaño JP, et al.
    (2008) Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. Peptides 29:711–720.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Milani-Nejad N and
    2. Janssen PM
    (2014) Small and large animal models in cardiac contraction research: advantages and disadvantages. Pharmacol Ther 141:235–249.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Nassour H,
    2. Iddir M, and
    3. Chatenet D
    (2019) Towards targeting the urotensinergic system: overview and challenges. Trends Pharmacol Sci 40:725–734.
    OpenUrl
  37. ↵
    1. Rapp JP
    (2000) Genetic analysis of inherited hypertension in the rat. Physiol Rev 80:135–172.
    OpenUrlPubMed
  38. ↵
    1. Ravera M,
    2. Ratto E,
    3. Vettoretti S,
    4. Parodi D, and
    5. Deferrari G
    (2005) Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol 16 (Suppl 1):S48–S52.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Richards AM,
    2. Nicholls MG,
    3. Lainchbury JG,
    4. Fisher S, and
    5. Yandle TG
    (2002) Plasma urotensin II in heart failure. Lancet 360:545–546.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Schulz A and
    2. Kreutz R
    (2012) Mapping genetic determinants of kidney damage in rat models. Hypertens Res 35:675–694.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Selye H,
    2. Bajusz E,
    3. Grasso S, and
    4. Mendell P
    (1960) Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11:398–407.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Sidharta PN,
    2. Rave K,
    3. Heinemann L,
    4. Chiossi E,
    5. Krähenbühl S, and
    6. Dingemanse J
    (2009) Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol 68:502–510.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Strowski MZ,
    2. Cashen DE,
    3. Birzin ET,
    4. Yang L,
    5. Singh V,
    6. Jacks TM,
    7. Nowak KW,
    8. Rohrer SP,
    9. Patchett AA,
    10. Smith RG, et al.
    (2006) Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist. Endocrinology 147:4664–4673.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Totsune K,
    2. Takahashi K,
    3. Arihara Z,
    4. Sone M,
    5. Ito S, and
    6. Murakami O
    (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104:1–5.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Tsoukas P,
    2. Kane E, and
    3. Giaid A
    (2011) Potential clinical implications of the urotensin II receptor antagonists. Front Pharmacol 2:38.
    OpenUrlPubMed
  46. ↵
    1. Vaudry H,
    2. Leprince J,
    3. Chatenet D,
    4. Fournier A,
    5. Lambert DG,
    6. Le Mével JC,
    7. Ohlstein EH,
    8. Schwertani A,
    9. Tostivint H, and
    10. Vaudry D
    (2015) International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev 67:214–258.
    OpenUrlCrossRef
  47. ↵
    1. Vogt L,
    2. Chiurchiu C,
    3. Chadha-Boreham H,
    4. Danaietash P,
    5. Dingemanse J,
    6. Hadjadj S,
    7. Krum H,
    8. Navis G,
    9. Neuhart E,
    10. Parvanova AI, et al., and PROLONG (PROteinuria Lowering with urOteNsin receptor antaGonists) Study Group
    (2010) Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension 55:1206–1209.
    OpenUrlCrossRef
  48. ↵
    1. Watson AM,
    2. Olukman M,
    3. Koulis C,
    4. Tu Y,
    5. Samijono D,
    6. Yuen D,
    7. Lee C,
    8. Behm DJ,
    9. Cooper ME,
    10. Jandeleit-Dahm KA, et al.
    (2013) Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. Diabetologia 56:1155–1165.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Yang T,
    2. Snyders D, and
    3. Roden DM
    (2001) Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38:737–744.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Zhu YZ,
    2. Wang ZJ,
    3. Zhu YC,
    4. Zhang L,
    5. Oakley RME,
    6. Chung CW,
    7. Lim KW,
    8. Lee HS,
    9. Ozoux ML,
    10. Linz W, et al.
    (2004) Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a “vasoconstrictor” with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 286:H830–H836.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleDrug Discovery and Translational Medicine

Urotensin II Receptor Antagonism in Chronic Kidney Disease

Marie-Laure Ozoux, Véronique Briand, Michel Pelat, Fabrice Barbe, Paul Schaeffer, Philippe Beauverger, Bruno Poirier, Jean-Michel Guillon, Frédéric Petit, Jean-Michel Altenburger, Jean-Pierre Bidouard and Philip Janiak
Journal of Pharmacology and Experimental Therapeutics July 1, 2020, 374 (1) 24-37; DOI: https://doi.org/10.1124/jpet.120.265496
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement